The ADMIRAL trial demonstrated that patients treated with 80 mg/d of gilteritinib have a tumor objective response rate (ORR) of 40% of all AML patients, regardless of whether they displayed the mutation—an ORR of 52% in those with the FLT3 mutation [87]. Here, FLT3 is linked to acute myeloid leukemia.